EA033198B1 - Оксадиазольные производные, пригодные в качестве ингибиторов hdac - Google Patents

Оксадиазольные производные, пригодные в качестве ингибиторов hdac

Info

Publication number
EA033198B1
EA033198B1 EA201890338A EA201890338A EA033198B1 EA 033198 B1 EA033198 B1 EA 033198B1 EA 201890338 A EA201890338 A EA 201890338A EA 201890338 A EA201890338 A EA 201890338A EA 033198 B1 EA033198 B1 EA 033198B1
Authority
EA
Eurasian Patent Office
Prior art keywords
hdac inhibitors
oxadiazole derivatives
derivatives useful
diseases
compound
Prior art date
Application number
EA201890338A
Other languages
English (en)
Other versions
EA201890338A1 (ru
Inventor
Акира Каиеда
Масаси Тоефуку
Масаки Даини
Хироси Нара
Масато Йосикава
Наоки Исии
Коусуке Хидака
Original Assignee
Такеда Фармасьютикал Компани Лимитед
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Такеда Фармасьютикал Компани Лимитед filed Critical Такеда Фармасьютикал Компани Лимитед
Publication of EA201890338A1 publication Critical patent/EA201890338A1/ru
Publication of EA033198B1 publication Critical patent/EA033198B1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/08—Bridged systems

Abstract

Изобретение относится к гетероциклическому соединению, обладающему ингибирующим HDAC действием и являющемуся пригодным для лечения аутоиммунных заболеваний и/или воспалительных заболеваний, реакции "трансплантат против хозяина", рака, заболеваний центральной нервной системы, включая нейродегенеративные заболевания, болезни Шарко-Мари-Тута и подобных, и фармацевтической композиции, содержащей данное соединение. Настоящее изобретение относится к соединению, представленному формулой (I)где каждый символ представляет собой, как определено в описании, или его соли.
EA201890338A 2015-07-17 2016-07-15 Оксадиазольные производные, пригодные в качестве ингибиторов hdac EA033198B1 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2015143354 2015-07-17
JP2016029020 2016-02-18
PCT/JP2016/071655 WO2017014321A1 (en) 2015-07-17 2016-07-15 Oxadiazole derivatives useful as hdac inhibitors

Publications (2)

Publication Number Publication Date
EA201890338A1 EA201890338A1 (ru) 2018-07-31
EA033198B1 true EA033198B1 (ru) 2019-09-30

Family

ID=56853775

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201890338A EA033198B1 (ru) 2015-07-17 2016-07-15 Оксадиазольные производные, пригодные в качестве ингибиторов hdac

Country Status (11)

Country Link
US (1) US10308643B2 (ru)
EP (1) EP3325475B1 (ru)
JP (1) JP6671456B2 (ru)
CN (1) CN108026088B (ru)
AU (1) AU2016297362B2 (ru)
BR (1) BR112018000906A2 (ru)
CA (1) CA2992700A1 (ru)
EA (1) EA033198B1 (ru)
ES (1) ES2793014T3 (ru)
TW (1) TW201713649A (ru)
WO (1) WO2017014321A1 (ru)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016031815A1 (ja) 2014-08-26 2016-03-03 武田薬品工業株式会社 複素環化合物
EP3325475B1 (en) 2015-07-17 2020-03-18 Takeda Pharmaceutical Company Limited Oxadiazole derivatives useful as hdac inhibitors
WO2017014170A1 (ja) 2015-07-17 2017-01-26 武田薬品工業株式会社 複素環化合物
JPWO2017033946A1 (ja) 2015-08-25 2018-06-07 武田薬品工業株式会社 複素環化合物
WO2017110863A1 (ja) * 2015-12-25 2017-06-29 住友化学株式会社 オキサジアゾール化合物及びその用途
US10357493B2 (en) 2017-03-10 2019-07-23 Selenity Therapeutics (Bermuda), Ltd. Metalloenzyme inhibitor compounds
JP7135007B2 (ja) * 2017-07-31 2022-09-12 武田薬品工業株式会社 複素環化合物
WO2019148005A1 (en) * 2018-01-26 2019-08-01 Nurix Therapeutics, Inc. Inhibitors of cbl-b and methods of use thereof
US20210009541A1 (en) * 2018-02-12 2021-01-14 Bayer Aktiengesellschaft Fungicidal oxadiazoles
KR102316234B1 (ko) 2018-07-26 2021-10-22 주식회사 종근당 히스톤 탈아세틸화효소 6 억제제로서의 1,3,4-옥사다이아졸 유도체 화합물 및 이를 포함하는 약제학적 조성물
KR20210077719A (ko) 2018-10-15 2021-06-25 누릭스 테라퓨틱스 인코포레이티드 유비퀴틴 프로테오좀 경로를 통해 btk를 분해시키기 위한 이작용성 화합물
CN111057069B (zh) * 2018-10-16 2024-01-26 武汉光谷通用名药物研究院有限公司 一种环状化合物、其应用及组合物
CN109293567A (zh) * 2018-11-23 2019-02-01 上海睿腾医药科技有限公司 一种5-溴-2-甲基烟酸乙酯的合成方法
EP3919055A4 (en) * 2019-01-30 2022-11-09 Takeda Pharmaceutical Company Limited HETEROCYCLIC COMPOUND
CA3136348A1 (en) 2019-04-09 2020-10-15 Nurix Therapeutics, Inc. 3-substituted piperidine compounds for cbl-b inhibition, and use of a cbl-b inhibitor in combination with a cancer vaccine and/or oncolytic virus
EP3969447A1 (en) 2019-05-17 2022-03-23 Nurix Therapeutics, Inc. Cyano cyclobutyl compounds for cbl-b inhibition and uses thereof
KR20220026581A (ko) * 2019-06-26 2022-03-04 누릭스 테라퓨틱스 인코포레이티드 Cbl-b 억제를 위한 치환된 벤질-트리아졸 화합물, 및 이의 추가의 용도
WO2021021761A1 (en) * 2019-07-30 2021-02-04 Nurix Therapeutics, Inc. Urea, amide, and substituted heteroaryl compounds for cbl-b inhibition
CN110498759A (zh) * 2019-09-12 2019-11-26 天津瑞岭化工有限公司 异吲哚啉酮类化合物的合成方法
BR112022005595A2 (pt) 2019-09-27 2022-07-19 Takeda Pharmaceuticals Co Composto, medicamento, métodos para inibir histona deacetilase 6 e para profilaxia ou tratamento de doença de alzheimer ou paralisia supranuclear progressiva em um mamífero, e, uso de composto
WO2021075476A1 (ja) * 2019-10-18 2021-04-22 武田薬品工業株式会社 複素環化合物
IL293797A (en) 2019-12-04 2022-08-01 Nurix Therapeutics Inc Bifunctional compounds for btk degradation via the ubiquitin proteosome pathway
CN111961020A (zh) * 2020-08-31 2020-11-20 南通大学 一种四氢吡喃羧酸衍生物及其合成方法
WO2022129196A1 (en) 2020-12-18 2022-06-23 Bayer Aktiengesellschaft Heterobicycle substituted 1,2,4-oxadiazoles as fungicides
WO2023081328A1 (en) * 2021-11-04 2023-05-11 Valo Health, Inc. Histone deacetylase 6 inhibitor compounds and uses thereof

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013066831A1 (en) * 2011-10-31 2013-05-10 Glaxosmithkline Llc Compounds and methods
WO2013080120A1 (en) * 2011-11-28 2013-06-06 Novartis Ag Novel trifluoromethyl-oxadiazole derivatives and their use in the treatment of disease

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7868008B2 (en) 2005-08-12 2011-01-11 Astrazeneca Ab Substituted isoindolones and their use as metabotropic glutamate receptor potentiators
CA2626897A1 (en) 2005-11-03 2007-05-18 Joshua Close Histone deacetylase inhibitors with aryl-pyrazolyl motifs
TWI417100B (zh) 2007-06-07 2013-12-01 Astrazeneca Ab 二唑衍生物及其作為代謝型麩胺酸受體增效劑-８４２之用途
JP5501227B2 (ja) 2007-06-27 2014-05-21 メルク・シャープ・アンド・ドーム・コーポレーション ヒストンデアセチラーゼ阻害剤としての４−カルボキシベンジルアミノ誘導体
AR077033A1 (es) 2009-06-11 2011-07-27 Hoffmann La Roche Compuestos inhibidores de las quinasas de janus y su uso en el tratamiento de enfermedades inmunologicas
US8981084B2 (en) 2010-01-13 2015-03-17 Tempero Pharmaceuticals, Inc. Oxadiazole HDAC inhibitors
US8901156B2 (en) 2010-01-13 2014-12-02 Tempero Pharmaceuticals, Inc. Compounds and methods
EP2712655B1 (en) 2011-04-28 2019-12-18 The Broad Institute, Inc. Inhibitors of histone deacetylase
WO2013006408A1 (en) 2011-07-01 2013-01-10 Tempero Pharmaceuticals, Inc. Compounds and methods
ES2556822T3 (es) 2011-07-08 2016-01-20 Novartis Ag Derivados de trifluorometil-oxadiazol novedosos y su uso en el tratamiento de enfermedad
WO2013009827A1 (en) 2011-07-13 2013-01-17 Tempero Pharmaceuticals, Inc. Methods of treatment
WO2013009830A1 (en) 2011-07-13 2013-01-17 Tempero Pharmaceuticals, Inc. Methods of treatment
WO2013009810A1 (en) 2011-07-13 2013-01-17 Tempero Pharmaceuticals, Inc. Methods of treatment
WO2013013113A2 (en) 2011-07-20 2013-01-24 The General Hospital Corporation Histone deacetylase 6 selective inhibitors for the treatment of bone disease
KR101812237B1 (ko) 2011-09-27 2017-12-27 코오롱인더스트리 주식회사 폴리에틸렌테레프탈레이트 연신사의 제조방법, 폴리에틸렌테레프탈레이트 연신사 및 타이어 코오드
WO2013066839A2 (en) 2011-10-31 2013-05-10 Glaxosmithkline Llc Compounds and methods
WO2013066838A1 (en) 2011-10-31 2013-05-10 Glaxosmithkline Llc Compounds and methods
WO2013066835A2 (en) 2011-10-31 2013-05-10 Glaxosmithkline Llc Compounds and methods
WO2013066833A1 (en) 2011-10-31 2013-05-10 Glaxosmithkline Llc Compounds and methods to inhibit histone deacetylase (hdac) enzymes
WO2016031815A1 (ja) 2014-08-26 2016-03-03 武田薬品工業株式会社 複素環化合物
WO2016039398A1 (ja) 2014-09-09 2016-03-17 国立大学法人大阪大学 含窒素複素環誘導体、神経保護剤及び癌治療用医薬組成物
WO2017014170A1 (ja) 2015-07-17 2017-01-26 武田薬品工業株式会社 複素環化合物
EP3325475B1 (en) 2015-07-17 2020-03-18 Takeda Pharmaceutical Company Limited Oxadiazole derivatives useful as hdac inhibitors
JPWO2017033946A1 (ja) 2015-08-25 2018-06-07 武田薬品工業株式会社 複素環化合物
WO2017110863A1 (ja) 2015-12-25 2017-06-29 住友化学株式会社 オキサジアゾール化合物及びその用途
WO2017222950A1 (en) 2016-06-23 2017-12-28 Merck Sharp & Dohme Corp. 3-heterocyclyl substituted 5-trifluoromethyl oxadiazoles as histone deacetylase 6 (hdac6) inhibitors
WO2017222952A1 (en) 2016-06-23 2017-12-28 Merck Sharp & Dohme Corp. 3- heteroaryl substituted 5-trifluoromethyl oxadiazoles as histone deacetylase 6 (hdac6) inhibitors
US11066396B2 (en) 2016-06-23 2021-07-20 Merck Sharp & Dohme Corp. 3-aryl- heteroaryl substituted 5-trifluoromethyl oxadiazoles as histonedeacetylase 6 (HDAC6) inhibitors

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013066831A1 (en) * 2011-10-31 2013-05-10 Glaxosmithkline Llc Compounds and methods
WO2013080120A1 (en) * 2011-11-28 2013-06-06 Novartis Ag Novel trifluoromethyl-oxadiazole derivatives and their use in the treatment of disease

Also Published As

Publication number Publication date
AU2016297362A1 (en) 2018-02-22
US20170015655A1 (en) 2017-01-19
JP6671456B2 (ja) 2020-03-25
CN108026088A (zh) 2018-05-11
US10308643B2 (en) 2019-06-04
ES2793014T3 (es) 2020-11-12
TW201713649A (zh) 2017-04-16
AU2016297362B2 (en) 2020-04-16
CA2992700A1 (en) 2017-01-26
EP3325475A1 (en) 2018-05-30
EP3325475B1 (en) 2020-03-18
CN108026088B (zh) 2021-02-12
EA201890338A1 (ru) 2018-07-31
BR112018000906A2 (pt) 2018-09-11
JP2018524378A (ja) 2018-08-30
WO2017014321A1 (en) 2017-01-26

Similar Documents

Publication Publication Date Title
EA033198B1 (ru) Оксадиазольные производные, пригодные в качестве ингибиторов hdac
MX2020011528A (es) Inhibidores heterociclicos sustituidos de ptpn11.
PH12017501817A1 (en) Heterocyclic compounds as lsd1 inhibitors
MX2016011035A (es) Compuestos arilo, heteroarilo y heterociclicos para el tratamiento de trastornos mediados por complemento.
PH12016502382A1 (en) Substituted indazole compounds as irak4 inhibitors
EA201990833A1 (ru) Соединение пиридина
PH12016501972B1 (en) Bicyclic-fused heteroaryl or aryl compounds and their use as irak4 inhibitors
TN2017000009A1 (en) Spirocycloheptanes as inhibitors of rock.
EA201692079A1 (ru) Ингибиторы лизин-специфической деметилазы-1
MX2018010374A (es) Inhibidores del enlace proteína-proteína de wdr5.
MX2017006266A (es) Compuestos de heteroarilo como inhibidores de cinasas asociadas al receptor de interleucina 1(irak) y sus usos.
EA201690952A1 (ru) Пиразол для лечения аутоиммунных расстройств
EA201790170A1 (ru) Терапевтические соединения-ингибиторы
PH12016501702B1 (en) Pyrazole amide derivative
PH12017501160A1 (en) 5-[(piperazin-1-yl)-3-oxo-propyl]-imidazolidine-2,4-dione derivatives as adamts inhibitors for the treatment of osteoarthritis
MY197698A (en) Oxysterols and methods of use thereof
EA033236B1 (ru) Новые производные пиразола в качестве ингибиторов nik
PH12016501462A1 (en) Neprilysin inhibitors
PH12015502611A1 (en) Heterocyclic compounds as hedgehog signaling pathway inhibitors
MX2018001992A (es) Compuestos triciclicos heterociclicos como inhibidores de fosfoinositol 3-quinasa.
WO2016004404A3 (en) Gls1 inhibitors for treating disease
PH12017500007A1 (en) Quinolizinone derivatives as p13k inhibitors
EA201992306A1 (ru) Ингибиторы ip6k
GEP20207130B (en) Imidazolone compounds as human neutrophil elastase inhibitors
EA201792425A1 (ru) Трициклические соединения и их применение в качестве ингибиторов фосфодиэстераз

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG TJ TM